sulbactam + ampicillin + azithromycin + amoxicillin

This antibiotic combination regimen consists of sulbactam, ampicillin, azithromycin, and amoxicillin. It is being evaluated in a randomized controlled trial conducted by Van Yuzuncu Yil University for the management of preterm premature rupture of membranes (PPROM) after 34 weeks of gestation. The regimen involves an initial 48-hour phase of intravenous sulbactam-ampicillin (4x2 g) and oral azithromycin (1 g on day 1), followed by a maintenance phase of oral amoxicillin (3x500 mg) from days 3 to 7. The combination utilizes multiple mechanisms to provide broad-spectrum coverage: ampicillin and amoxicillin are beta-lactam antibiotics that inhibit bacterial cell wall synthesis; sulbactam is a beta-lactamase inhibitor that prevents the degradation of these penicillins by resistant bacteria; and azithromycin is a macrolide that inhibits bacterial protein synthesis. The primary clinical objective is to optimize maternal and neonatal outcomes, specifically targeting a reduction in neonatal intensive care unit (NICU) length of stay.

Other names

Antibiotic regimen 1sulbactam + ampicillin + azithromycin